KR20230046177A - Oral composition comprising sericin for inhibiting the halitosis - Google Patents
Oral composition comprising sericin for inhibiting the halitosis Download PDFInfo
- Publication number
- KR20230046177A KR20230046177A KR1020210185136A KR20210185136A KR20230046177A KR 20230046177 A KR20230046177 A KR 20230046177A KR 1020210185136 A KR1020210185136 A KR 1020210185136A KR 20210185136 A KR20210185136 A KR 20210185136A KR 20230046177 A KR20230046177 A KR 20230046177A
- Authority
- KR
- South Korea
- Prior art keywords
- sericin
- weight
- present
- oral
- composition
- Prior art date
Links
- 108010013296 Sericins Proteins 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 206010006326 Breath odour Diseases 0.000 title claims abstract description 24
- 230000002401 inhibitory effect Effects 0.000 title abstract description 10
- 208000032139 Halitosis Diseases 0.000 title abstract description 7
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 44
- 241000241413 Propolis Species 0.000 claims description 27
- 229940069949 propolis Drugs 0.000 claims description 27
- 229940107702 grapefruit seed extract Drugs 0.000 claims description 26
- 229940094952 green tea extract Drugs 0.000 claims description 25
- 235000020688 green tea extract Nutrition 0.000 claims description 25
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 24
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 24
- 239000000811 xylitol Substances 0.000 claims description 24
- 235000010447 xylitol Nutrition 0.000 claims description 24
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 24
- 229960002675 xylitol Drugs 0.000 claims description 24
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 22
- 229960000458 allantoin Drugs 0.000 claims description 22
- 241000255789 Bombyx mori Species 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000002324 mouth wash Substances 0.000 abstract description 26
- 230000000694 effects Effects 0.000 abstract description 18
- 239000004615 ingredient Substances 0.000 abstract description 9
- 230000000052 comparative effect Effects 0.000 description 25
- 210000000214 mouth Anatomy 0.000 description 23
- 238000011156 evaluation Methods 0.000 description 22
- 230000000844 anti-bacterial effect Effects 0.000 description 21
- 229940051866 mouthwash Drugs 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 16
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 11
- 241000194019 Streptococcus mutans Species 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 241000605862 Porphyromonas gingivalis Species 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 208000002925 dental caries Diseases 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 102000004890 Interleukin-8 Human genes 0.000 description 5
- 108090001007 Interleukin-8 Proteins 0.000 description 5
- 239000010408 film Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229940034610 toothpaste Drugs 0.000 description 5
- 239000000606 toothpaste Substances 0.000 description 5
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 4
- 229960003260 chlorhexidine Drugs 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 208000028169 periodontal disease Diseases 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 3
- 240000000560 Citrus x paradisi Species 0.000 description 3
- 108010022355 Fibroins Proteins 0.000 description 3
- 229920001503 Glucan Polymers 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000025157 Oral disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000003298 dental enamel Anatomy 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000030194 mouth disease Diseases 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 2
- 241000186044 Actinomyces viscosus Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010016322 Feeling abnormal Diseases 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 102000000340 Glucosyltransferases Human genes 0.000 description 2
- 108010055629 Glucosyltransferases Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 241001135221 Prevotella intermedia Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 108010007119 flavourzyme Proteins 0.000 description 2
- 229940091249 fluoride supplement Drugs 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 229930019673 naringin Natural products 0.000 description 2
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 2
- 229940052490 naringin Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 150000003464 sulfur compounds Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- ZZPQSQFQHIGCRC-OOFFSTKBSA-N (2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-c Chemical compound [Zn].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ZZPQSQFQHIGCRC-OOFFSTKBSA-N 0.000 description 1
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 241001024600 Aggregatibacter Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000004173 Cathepsin G Human genes 0.000 description 1
- 108090000617 Cathepsin G Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000000882 Citrus x paradisi Nutrition 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101000578920 Homo sapiens Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102100028322 Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 Human genes 0.000 description 1
- 208000005736 Nervous System Malformations Diseases 0.000 description 1
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 241001135235 Tannerella forsythia Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 208000004509 Tooth Discoloration Diseases 0.000 description 1
- 206010044032 Tooth discolouration Diseases 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229940078495 calcium phosphate dibasic Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- PMDSRSSLWQASHS-UHFFFAOYSA-N pyridin-1-ium;chloride;hydrate Chemical compound O.Cl.C1=CC=NC=C1 PMDSRSSLWQASHS-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000036367 tooth discoloration Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037330 wrinkle prevention Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
- A61K8/988—Honey; Royal jelly, Propolis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Zoology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 저분자 세리신 및 다양한 천연 성분을 포함하는 구취 억제용 구강 조성물에 관한 것이다.The present invention relates to an oral composition for suppressing bad breath comprising low molecular weight sericin and various natural ingredients.
최근 건강의 개념이 사화생활 개념으로 변화되면서 구강 건강에 대한 개념도 변화되고 구강 질환의 예방과 치료 및 재활에 대한 수요의 증가 뿐만 아니라 사회생활의 장애가 되는 구취의 예방과 제거에 대한 관심도 증가하고 있는 추세이다. 또한, 현대인들의 사회활동 증가로 사람들 간의 접촉은 많아지고 시간은 촉박해지면서 외출 시 간편하게 입안을 헹구어 구취 제거나 구강 세정, 구강질환 예방 등의 효과를 얻을 수 있는 구강 청결제가 점차 보편화되고 있다. 구강 청결제란 제품의 특성을 강조하기 위해 구강 청량제, 구강 세척제, 구강 양치액 또는 가글액으로 많이 알려져 있으나, 의약외품 범위 지정에 따른 정식 명칭은 구중 청량제이다 (Journal of Korean Society of Dental Hygiene, 15(2): 319-324, 2015). Recently, as the concept of health has changed to the concept of social life, the concept of oral health has also changed, and the demand for prevention, treatment, and rehabilitation of oral diseases is increasing, as well as interest in the prevention and removal of bad breath, which is an obstacle in social life, is increasing. am. In addition, with the increase in social activities of modern people, contact between people increases and time becomes tight, and mouthwashes that can easily rinse the mouth when going out to remove bad breath, wash the mouth, and prevent oral diseases are becoming more common. Mouthwash is often known as mouth freshener, mouthwash, mouthwash, or gargle to emphasize the characteristics of the product, but the official name according to the designation of quasi-drugs is oral freshener (Journal of Korean Society of Dental Hygiene, 15(2): 319-324, 2015).
구강 청결제의 사용은 구강 내에 남아있는 음식물 잔사나 약하게 부착되어 있는 치면 세균막을 제거하고, 상쾌한 맛을 내게 하거나 구취 제거를 도우며, 구강 미생물의 수를 일시적으로 줄여주는데 그 목적이 있다. 또한, 충치를 예방하고 치태 생성을 억제하는 기능이 알려져 있으며, 종류에 따라서는 입 속의 상처나 궤양, 잇몸이나 인후의 염증을 완화시키는 효과도 있다. 따라서, 구강 청결제의 주요 성분은 우식을 예방하기 위한 목적의 불화물이나 구강 내 미생물의 감소를 위한 항균제, 염증 완화제, 감미제, 에틸알코올 및 증류수 등이며, 보존성을 높이기 위하여 보존제를 첨가하고 있다. The purpose of the use of mouthwash is to remove food residues remaining in the oral cavity or weakly adhered bacterial film on the tooth surface, to give a refreshing taste or help to remove bad breath, and to temporarily reduce the number of oral microorganisms. In addition, the function of preventing tooth decay and suppressing the formation of plaque is known, and depending on the type, there is also an effect of relieving wounds or ulcers in the mouth, inflammation of the gums or throat. Therefore, the main components of the mouthwash are fluoride for the purpose of preventing caries, antibacterial agents for reducing oral microorganisms, anti-inflammatory agents, sweeteners, ethyl alcohol and distilled water, etc., and preservatives are added to improve preservation.
국민소득과 생활수준이 향상으로 구강건강에 대한 관심이 증가되면서 구강 청결제의 성분과 효능에 대한 관심 또한 높아지고 있으며, 최근의 개발 경향은 구강 청결제의 이물질 제거 효능뿐 아니라 치료제까지 도약 개발되고 있는 것이 현실이다. 특히, 구강 청결제는 구강 위생 관리에 사용되는 보조 용품으로 치약, 칫솔 다음으로 사용률이 높고, 최근 다양한 종류의 구강 청결제가 출시되면서 구강 청결제의 시장 규모도 지속적으로 증가하고 있다. 그러나, 그러나, 종래의 구강 청결제는 특유의 알콜 향 및 자극감을 나타내어 사용감에 대한 평가가 부정적이었으며, 장기간 사용 시 미량씩 인체 내로 섭취될 가능성이 있고, 정상 균주의 변화를 일으켜 구강 내 환경에 부정적인 영향을 미칠 가능성이 제기되고 있다. 따라서, 천연 성분을 이용하여 보다 효과적이고 부작용이 적은 구강 청결제의 개발이 필수적이다.As interest in oral health increases with the improvement of national income and standard of living, interest in the ingredients and efficacy of mouthwash is also increasing. am. In particular, mouthwash is an auxiliary product used for oral hygiene management, and its usage rate is high next to toothpaste and toothbrush. However, however, the conventional mouthwash exhibits a unique alcohol scent and irritation, so the evaluation of the feeling of use is negative, and there is a possibility of being ingested into the human body in small amounts when used for a long time, and it causes a change in normal strains, which negatively affects the oral environment possibility is being raised. Therefore, it is essential to develop mouthwashes that are more effective and have fewer side effects using natural ingredients.
한편, 세리신(sericin)은 실크 피브로인을 둘러싸고 있는 접착성 물질로서 누에가 방사하는 고치실의 20~30%를 차지하고 있는 중요한 천연 자원이다. 실크 섬유의 정련 과정에서 세리신을 제거하게 되면, 외형적인 구조 변화에 따라 광택이 향상되고 촉감이 부드러워 의복 재료로서 상업적으로 우수한 가치를 갖게 된다. 이러한 이유로, 오랫동안 실크 산업에서 세리신은 버려지는 폐기물로 간주되어 왔다 (J Seric Entomol Sci 55(2), 44-53, 2019). On the other hand, sericin (sericin) is an adhesive material surrounding silk fibroin and is an important natural resource that accounts for 20 to 30% of cocoon threads emitted by silkworms. When sericin is removed during the refining process of silk fiber, gloss is improved and the touch is soft according to the external structure change, so it has excellent commercial value as a clothing material. For this reason, sericin has long been considered a discarded waste in the silk industry (J Seric Entomol Sci 55(2), 44-53, 2019).
이러한 배경 하에, 본 발명자들은 세리신을 구강 위생용 소재로써 활용하기 위해 예의 노력한 결과, 저분자 세리신의 활성이 우수한 것을 확인하였으며, 세리신 및 다양한 천연 성분을 포함하는 구강 조성물이 우수한 항균 활성 및 구취 제거 활성을 나타내는 것을 확인하여 본 발명을 완성하였다.Under this background, the present inventors made diligent efforts to utilize sericin as an oral hygiene material, and as a result, it was confirmed that low molecular weight sericin had excellent activity, and an oral composition containing sericin and various natural ingredients had excellent antibacterial activity and bad breath removal activity. The present invention was completed by confirming what was shown.
본 발명의 하나의 목적은 저분자 세리신, 알란토인, 프로폴리스, 자일리톨, 자몽종자 추출물, 및 녹차 추출물을 포함하는 구강 조성물을 제공하는 것이다.One object of the present invention is to provide an oral composition comprising low molecular weight sericin, allantoin, propolis, xylitol, grapefruit seed extract, and green tea extract.
본 발명의 다른 목적은 (a) 누에고치를 80 내지 90℃에서 6 내지 10시간 동안 열수 추출하는 단계; (b) 50 내지 55℃에서 5 내지 7시간 동안 3%(w/w) 액티나제를 상기 추출물에 처리하여 저분자 세리신을 수득하는 단계; 및 (c) 상기 저분자 세리신, 알란토인, 프로폴리스, 자일리톨, 자몽종자 추출물, 및 녹차 추출물을 혼합하는 단계;를 포함하는, 구강 조성물의 제조방법을 제공하는 것이다.Another object of the present invention is (a) hot water extraction of silkworm cocoons at 80 to 90 ° C. for 6 to 10 hours; (b) treating the extract with 3% (w/w) actinase at 50 to 55° C. for 5 to 7 hours to obtain low molecular weight sericin; And (c) mixing the low-molecular-weight sericin, allantoin, propolis, xylitol, grapefruit seed extract, and green tea extract; to provide a method for preparing an oral composition comprising the.
본 발명의 다른 목적은 상기 구강 조성물을 포함하는 구강 청결제를 제공하는 것이다.Another object of the present invention is to provide a mouthwash comprising the oral composition.
본 발명의 또 다른 목적은 저분자 세리신, 알란토인, 프로폴리스, 자일리톨, 자몽종자 추출물, 및 녹차 추출물을 포함하는 항균용 조성물을 제공하는 것이다.Another object of the present invention is to provide an antibacterial composition comprising low molecular weight sericin, allantoin, propolis, xylitol, grapefruit seed extract, and green tea extract.
이를 구체적으로 설명하면 다음과 같다. 한편, 본 발명에서 개시된 각각의 설명 및 실시형태는 각각의 다른 설명 및 실시 형태에도 적용될 수 있다. 즉, 본 발명에서 개시된 다양한 요소들의 모든 조합이 본 발명의 범주에 속한다. 또한, 하기 기술된 구체적인 서술에 의하여 본 발명의 범주가 제한된다고 볼 수 없다.A detailed description of this is as follows. Meanwhile, each description and embodiment disclosed in the present invention may also be applied to each other description and embodiment. That is, all combinations of the various elements disclosed herein fall within the scope of the present invention. In addition, it cannot be seen that the scope of the present invention is limited by the specific descriptions described below.
상기 목적을 달성하기 위한 본 발명의 하나의 양태는, 저분자 세리신, 알란토인, 프로폴리스, 자일리톨, 자몽종자 추출물, 및 녹차 추출물을 포함하는 구강 조성물을 제공한다.One aspect of the present invention for achieving the above object provides an oral composition comprising low molecular weight sericin, allantoin, propolis, xylitol, grapefruit seed extract, and green tea extract.
본 발명의 용어 "세리신(sericin)"은 천연 단백질 중 하나로, 누에고치의 20~30%를 차지하며, 누에고치 실의 표면을 피복하고 있으므로 외부의 자극으로부터 피브로인(fibroin)을 보호하는 것으로 알려져 있다. 세리신을 구성하고 있는 주요 아미노산 조성은 serine, aspartic acid, alanine 순이며, 반응성 아미노산이 비교적 많이 포함되어 있다. 최근 들어 세리신에 대한 많은 연구를 통해 세리신이 상처치유 능력을 가지고 있으며, 우수한 자외선 저항성, 산화 저항성, 주름 방지성, 보습성을 가지고 있다는 연구 결과가 보고되어 있다. 그에 따라 세리신을 화장품과 의료용 소재로 응용하기 위한 연구들이 다수 진행되고 있으며, 섬유, 겔, 스펀지, 필름, 입자 또는 비드, 크림 등으로 성형을 위한 연구가 다양하게 수행되어 왔다. 다만, 세리신의 분자량에 따른 활성 차이를 평가하고, 세리신을 구강 위생 소재로써 활용하려는 시도는 보고된 바 없다.The term "sericin" of the present invention is one of the natural proteins, which accounts for 20 to 30% of cocoons, and is known to protect fibroin from external stimuli because it covers the surface of cocoon threads. . The composition of the main amino acids constituting sericin is in the order of serine, aspartic acid, and alanine, and a relatively large number of reactive amino acids are included. Recently, through many studies on sericin, it has been reported that sericin has a wound healing ability, and has excellent ultraviolet resistance, oxidation resistance, wrinkle prevention, and moisturizing properties. Accordingly, a number of studies have been conducted to apply sericin to cosmetics and medical materials, and various studies have been conducted for molding into fibers, gels, sponges, films, particles or beads, creams, and the like. However, no attempt has been made to evaluate the difference in activity according to the molecular weight of sericin and to utilize sericin as an oral hygiene material.
본 발명의 세리신은 저분자량을 가지는 것이며, 저분자량이란 2,000 내지 5,000, 구체적으로 2,000 내지 3,000Da의 분자량을 의미한다. 세리신의 일반적인 분자량은 27,000 내지 30,000인 것으로 알려져 있으나, 효소 처리에 의하여 저분자화 할 수 있다.The sericin of the present invention has a low molecular weight, and the low molecular weight means a molecular weight of 2,000 to 5,000, specifically 2,000 to 3,000 Da. Although the general molecular weight of sericin is known to be 27,000 to 30,000, it can be reduced in molecular weight by enzymatic treatment.
본 발명의 저분자 세리신은 누에고치를 열수 추출 후, 액티나제(actinase)를 처리하여 제조되는 것이다. 일반적으로, 누에고치로부터 세리신 단백질의 회수를 목적으로 하는 정련은 알칼리 처리 또는 고온고압법을 통해 추출하는 것으로 알려져 있다. 그에 반해, 본 발명에서는 열수 추출 및 효소 처리를 통하여 간단한 방법으로 저분자 세리신을 수득할 수 있다.The low-molecular-weight sericin of the present invention is prepared by extracting silkworm cocoons with hot water and then treating them with actinase. In general, it is known that refining for the purpose of recovering sericin protein from silkworm cocoons is extracted through alkali treatment or high-temperature and high-pressure method. In contrast, in the present invention, low molecular weight sericin can be obtained by a simple method through hot water extraction and enzyme treatment.
본 발명의 구체적인 일 구현예에서는, 누에고치를 열수 추출한 후, 액티나제(actinase) 또는 플라보르자임(flavourzyme) 효소를 각각 처리하여 수득한 세리신의 분자량을 측정한 결과, 액티나제를 처리하여 수득한 세리신은 약 2,790Da의 분자량, 플라보르자임을 처리하여 수득한 세리신은 약 10,040Da의 분자량을 나타내는 것을 확인하였다 (평가예 1).In a specific embodiment of the present invention, as a result of measuring the molecular weight of sericin obtained by hot water extraction of silkworm cocoons and treatment with actinase or flavourzyme enzymes, respectively, actinase was treated It was confirmed that the obtained sericin had a molecular weight of about 2,790 Da, and the sericin obtained by treatment with flavorzyme had a molecular weight of about 10,040 Da (Evaluation Example 1).
본 발명의 다른 구체적인 일 구현예에서는, 저분자량을 나타내는 액티나제 처리 세리신 및 상대적으로 고분자량을 나타내는 플라보르자임 처리 세리신의 in vitro 항염 활성을 비교하였다. 그 결과, 고분자 세리신을 처리한 경우에 비하여, 저분자 세리신을 처리한 경우 LPS 유도에 의한 IL-6 및 IL-8의 발현량이 더욱 크게 감소한 것을 확인하였다 (평가예 2). 즉, 본 발명은 간단한 방법으로 저분자 세리신을 수득할 수 있는 방법을 규명하였으며, 구강 조성물에 상기 저분자 세리신을 이용함으로써 항염 활성을 더욱 향상시킬 수 있음을 확인하였다.In another specific embodiment of the present invention, the in vitro anti-inflammatory activity of actinase-treated sericin having a low molecular weight and flavorzyme-treated sericin having a relatively high molecular weight was compared. As a result, it was confirmed that the expression levels of IL-6 and IL-8 by LPS induction decreased more significantly when treated with low-molecular sericin compared to when treated with high-molecular sericin (Evaluation Example 2). That is, the present invention identified a method for obtaining low-molecular-weight sericin by a simple method, and it was confirmed that the anti-inflammatory activity could be further improved by using the low-molecular-weight sericin in an oral composition.
본 발명의 용어 "알란토인(allantoin)"은 화학식 C4H6N4O3이며, 컴프리, 밀의 싹에서 추출되는 천연 성분이다. 알란토인은 세포의 활동을 촉진시켜 염증 완화에 사용되며, 새로운 상피세포의 성장을 자극해 상처 치료에 효과적인 것으로 알려져 있다. The term "allantoin" in the present invention has the chemical formula C 4 H 6 N 4 O 3 and is a natural component extracted from the shoots of comfrey and wheat. Allantoin is used to relieve inflammation by promoting cell activity and is known to be effective in wound healing by stimulating the growth of new epithelial cells.
본 발명의 용어 "프로폴리스(propolis)"는 우리나라에서 1995년 식품 공전에 등재된 천연 물질로 벌집에서 얻어지는 지용성 복합체이며, 식물이 꽃봉오리와 생장점을 보호하기 위해 분비하는 왁스와 수지 물질을 모아 벌 자신의 침샘 분비물과 혼합하여 만든 수지성, 점착성, 고무상의 물질이다. 꿀벌은 프로폴리스를 벌집 출입구에 발라 외부로부터 균의 유입을 막기 위해 사용하며, 주로 벌통 내의 표면 틈새에 발라 빗물과 냉기를 막고, 벌집 전체 구조를 강화하기 위해 사용한다. 프로폴리스에는 각종 유기물과 플라보노이드(flavonoid)가 다량 함유되어 있으며 성분 중 플라보노이드는 강력한 항균효과를 가지는 것으로 보고되고 있다.The term "propolis" of the present invention is a natural substance registered in the Food Code in 1995 in Korea and is a fat-soluble complex obtained from beehives. It is a resinous, viscous, rubbery substance made by mixing with the secretions of one's own salivary glands. Bees use propolis to prevent the entry of bacteria from the outside by applying propolis to the entrance of the hive, and it is mainly used to prevent rainwater and cold air by applying propolis to the surface gaps in the hive and to strengthen the overall structure of the hive. Propolis contains a large amount of various organic substances and flavonoids, and among the components, flavonoids are reported to have a strong antibacterial effect.
본 발명의 용어 "자일리톨(xylitol)"은 pentose-sugar alcohol이라 불리는 천연 감미료로, 구강 내에서 대표적인 충치 발생균인 뮤탄스 (Streptococcus mutans) 균이 산을 생성하는 것을 억제하며, 치아 표면의 세균막인 프라그의 형성을 감소시켜 pH 저하를 억제함으로써 충치 예방 기능을 수행한다고 알려져 있다.The term "xylitol" of the present invention is a natural sweetener called pentose-sugar alcohol, which inhibits the production of acid by Streptococcus mutans , a representative cavity-causing bacterium in the oral cavity, and is a bacterial film on the tooth surface. It is known to perform the function of preventing tooth decay by suppressing the decrease in pH by reducing the formation of plaque.
본 발명의 용어 "자몽종자 추출물(Grapefruit Seed Extract)"은 운향과 자몽(Citrus paradisi MACF.)의 종자를 추출하여 얻어지는 것으로 주성분은 지방산, 플라보노이드 등이다. 자몽종자 추출물은 유효 성분으로써 나린진(naringin)을 90~130% 함유하며, 천연 항균 및 항산화제로 사용된다. 본 발명에서 자몽종자 추출물은 자몽종자를 물, 에탄올 또는 글리세린으로 추출하는 것일 수 있으며, 바람직하게는 글리세린으로 추출한 것이다. 상기 자몽종자 추출물은 다량의 천연 아스코르빈산, 나린진 및 토코페롤을 함유하고 있어 각종 식품에 대한 항균 및 항산화 작용이 뛰어나며, 지방의 산패를 방지한다.The term "Grapefruit Seed Extract" of the present invention is obtained by extracting seeds of rue and grapefruit ( Citrus paradisi MACF.), and its main components are fatty acids, flavonoids, and the like. Grapefruit seed extract contains 90 to 130% of naringin as an active ingredient, and is used as a natural antibacterial and antioxidant agent. In the present invention, the grapefruit seed extract may be obtained by extracting grapefruit seeds with water, ethanol or glycerin, preferably with glycerin. The grapefruit seed extract contains a large amount of natural ascorbic acid, naringin and tocopherol, so it has excellent antibacterial and antioxidant effects on various foods and prevents fat from rancidity.
본 발명의 용어 "녹차 추출물(Green Tea Extract)"은 차나무과 차나무(Camellia sinensis)의 잎을 추출하여 얻어지는 것으로 주성분은 카테킨류이다. 본 발명에서 녹차 추출물은 차나무의 잎을 물 또는 에탄올로 추출하는 것일 수 있으며, 바람직하게는 물로 추출한 것이다. 녹차 추출물은 카테킨을 다량 함유하고 있어 항산화 효과 및 항균 효과 등이 뛰어난 것으로 알려져 있다.The term "Green Tea Extract" of the present invention is obtained by extracting the leaves of Camellia sinensis, the main component of which is catechins. In the present invention, the green tea extract may be obtained by extracting tea leaves with water or ethanol, and is preferably extracted with water. Green tea extract is known to have excellent antioxidant and antibacterial effects because it contains a large amount of catechin.
본 발명의 알란토인, 프로폴리스, 자일리톨, 자몽종자 추출물, 및 녹차 추출물은 직접 합성 또는 추출하여 사용하거나, 시중에 판매되는 제품을 구입하는 등 그 수득 방법은 제한되지 않는다.Allantoin, propolis, xylitol, grapefruit seed extract, and green tea extract of the present invention are directly synthesized or extracted and used, or commercially available products are purchased.
본 발명의 구강 조성물은 저분자 세리신 5 내지 15 중량부, 알란토인 35 내지 45 중량부, 프로폴리스 15 내지 25 중량부, 자몽종자 추출물 0.1 내지 10 중량부, 자일리톨 5 내지 15 중량부, 및 녹차 추출물 0.1 내지 3 중량부를 포함하는 것일 수 있으며, 구체적으로, 저분자 세리신 10 중량부, 알란토인 40 중량부, 프로폴리스 20 중량부, 자몽종자 추출물 5 중량부, 자일리톨 10 중량부, 및 녹차 추출물 1 중량부를 포함하는 것일 수 있다.The oral composition of the present invention contains 5 to 15 parts by weight of low molecular weight sericin, 35 to 45 parts by weight of allantoin, 15 to 25 parts by weight of propolis, 0.1 to 10 parts by weight of grapefruit seed extract, 5 to 15 parts by weight of xylitol, and 0.1 to 15 parts by weight of green tea extract. It may contain 3 parts by weight, specifically, containing 10 parts by weight of low molecular weight sericin, 40 parts by weight of allantoin, 20 parts by weight of propolis, 5 parts by weight of grapefruit seed extract, 10 parts by weight of xylitol, and 1 part by weight of green tea extract can
본 발명의 구강 조성물은 구취 억제 효과를 나타내는 것을 특징으로 한다. 삶의 질적인 면이 강조되고 대인관계가 중요해지는 사회구조 속에서, 현대인은 자신과 타인의 구취로 인한 불편감에 더욱 민감해지고 있다. 구취는 입에서 불쾌한 냄새가 나는 증상을 의미하며, 호흡, 대화 및 저작 시 구강을 통해 발생한다. 구취의 원인은 생리적 원인, 병리적 원인 및 심리적 원인으로 나눌 수 있으며, 이 가운데 구취의 발생은 대부분 구강 내 원인이 작용하는 것으로 알려져 있다. 주로 구강 내에 존재하는 혐기성 그람음성 세균에 의해 음식물 찌꺼기, 탈락한 구강 점막의 상피세포, 치주낭에서 유래된 백혈구 및 타액 등의 단백질이 분해되어 발생하는 휘발성 황화합물(volatile sulfur compound, VSC)로 인해 유발되는 것으로 알려져 있다. 따라서, 구취 억제를 위해서는 근본적으로 구강 내에 존재하는 유해균을 억제하는 것이 중요하다.The oral composition of the present invention is characterized in that it exhibits an effect of suppressing bad breath. In a social structure where the quality of life is emphasized and interpersonal relationships are important, modern people are becoming more sensitive to discomfort caused by bad breath in themselves and others. Bad breath refers to symptoms of an unpleasant odor from the mouth, which occurs through the oral cavity during breathing, talking, and chewing. Causes of bad breath can be divided into physiological causes, pathological causes, and psychological causes. It is caused by volatile sulfur compound (VSC), which is generated when proteins such as food debris, exfoliated oral mucosal epithelial cells, white blood cells and saliva derived from periodontal pockets are decomposed by anaerobic gram-negative bacteria mainly present in the oral cavity. It is known. Therefore, in order to suppress bad breath, it is important to fundamentally suppress harmful bacteria present in the oral cavity.
본 발명의 구체적인 일 구현예에서는, 저분자 세리신, 알란토인, 프로폴리스, 자일리톨, 자몽종자 추출물, 및 녹차 추출물을 상이한 중량비로 포함하는 실시예 및 비교예 조성물의 구취 제거 활성을 비교한 결과, 저분자 세리신 10 중량부, 알란토인 40 중량부, 프로폴리스 20 중량부, 자몽종자 추출물 5 중량부, 자일리톨 10 중량부, 및 녹차 추출물 1 중량부를 포함하는 실시예 1 조성물의 구취 억제 활성이 가장 높은 것을 확인한 바 (평가예 3), 본 발명은 다양한 천연 성분들을 포함하면서 가장 우수한 구취 억제 효과를 가지는 구강 조성물의 혼합비를 규명한 것에 그 특징이 있다.In a specific embodiment of the present invention, low-molecular-weight sericin, allantoin, propolis, xylitol, grapefruit seed extract, and green tea extract in different weight ratios, as a result of comparing the bad breath removal activity of the compositions of Examples and Comparative Examples, low-molecular sericin 10 It was confirmed that the composition of Example 1 including 40 parts by weight of allantoin, 20 parts by weight of propolis, 5 parts by weight of grapefruit seed extract, 10 parts by weight of xylitol, and 1 part by weight of green tea extract had the highest halitosis inhibitory activity (evaluation Example 3), the present invention is characterized by identifying the mixing ratio of an oral composition containing various natural ingredients and having the best effect of suppressing bad breath.
본 발명의 구강 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 특별히 제한되는 것은 아니다. 본 발명의 구강 조성물은 분말상, 젤상, 점액상 및 액상 형태일 수 있으며, 이에 제한되지 않는다. 본 발명의 구강 조성물이 파우치 형태로 포장된 구강 청결제에 포함되는 경우, 액상 형태인 것이 바람직하다.The oral composition of the present invention may be prepared in any formulation commonly prepared in the art, and is not particularly limited. The oral composition of the present invention may be in powder form, gel form, mucus form and liquid form, but is not limited thereto. When the oral composition of the present invention is included in a mouthwash packaged in a pouch form, it is preferably in liquid form.
본 발명에 따른 구강 조성물은 상기 저분자 세리신, 알란토인, 프로폴리스, 자일리톨, 자몽종자 추출물, 및 녹차 추출물 외에 구강 조성물에 통상적으로 이용되는 성분들을 포함할 수 있다. 예컨대, 상기 성분들로는 연마제, 습윤제, 결합제, 기포제, 감미제, 방부제, 약효성분, 향미제, 색소, 용제, 증백제, 가용화제 또는 pH 조절제를 포함할 수 있다.The oral composition according to the present invention may include components commonly used in oral compositions other than the low molecular weight sericin, allantoin, propolis, xylitol, grapefruit seed extract, and green tea extract. For example, the components may include an abrasive, a wetting agent, a binder, a foaming agent, a sweetening agent, a preservative, a medicinal ingredient, a flavoring agent, a colorant, a solvent, a brightening agent, a solubilizing agent, or a pH adjusting agent.
상기 습윤제는 치약의 경우 분말이 페이스트 상이 되게 하고 조성물이 공기 중에 굳는 것을 방지하기 위한 것으로, 글리세린, 솔비트액, 프로필렌글리콜, 폴리에틸렌글리콜 등을 단독 또는 2종 이상 혼합하여 조성물에 포함될 수 있다. 상기 기포제는 조성물을 구강 중에 확산시켜 세정 효과를 높이고, 계면활성제로서 작용하여 구강 오염을 세정하는 것으로, 라우릴황산나트륨, 라우릴사르코신산나트륨, 자당지방산에스테르 등의 계면활성제를 단독 또는 2종 이상 혼합하여 조성물에 포함될 수 있다. 상기 결합제는 조성물 중의 분말과 액체 성분 간의 분리를 방지하기 위한 것으로, 카복시메틸셀룰로오스나트륨, 메틸셀룰로오스, 하이드록시프로필셀룰로오스 등의 셀룰로오스 유도체와 알긴산나트륨, 카라기난, 잔탄검 등을 단독 또는 2종 이상 혼합하여 조성물에 포함될 수 있다. 상기 연마제는 치아 표면을 상처를 내지 않고 치아 표면의 부착물을 제거하여 치아 본래의 광택이 나도록 하는 것으로, 탄산칼슘(CaCO3), 제2인산칼슘(CaHPO4, CaHPO4·2H2O), 무수규산(SiO2·2H2O), 수산화알루미늄(Al(OH)3), 피로인산칼륨, 탄산마그네슘 등을 단독 또는 2종 이상 혼합하여 조성물에 포함될 수 있다. 상기 감미제는 치약제 원료에 의한 불쾌한 맛을 제거하고 청량감을 좋게 만드는 것으로, 사카린산, 아스파탐, 자일리톨, 감초산 등을 단독 또는 2종 이상 혼합하여 조성물에 포함될 수 있다. 상기 약효성분은 치아 우식증, 치주질환 및 치은염의 예방, 또는 구취 제거 등의 효과를 위한 것으로, 불화물, 염화아연, 클로르헥시딘, 아미노카프론산, 트라넥사민산, 염화세틸피리디움, 염화피리독신, 트리클로산, 초산토코페롤, 일불소인산나트륨 등을 단독 또는 2종 이상 혼합하여 조성물에 포함될 수 있다.In the case of toothpaste, the humectant is used to make the powder paste and prevent the composition from hardening in the air, and may include glycerin, sorbitol, propylene glycol, polyethylene glycol, or the like alone or in combination of two or more. The foaming agent diffuses the composition into the oral cavity to increase the cleaning effect and acts as a surfactant to clean oral contamination. and can be included in the composition. The binder is for preventing separation between powder and liquid components in the composition, and cellulose derivatives such as sodium carboxymethylcellulose, methylcellulose, and hydroxypropylcellulose, and sodium alginate, carrageenan, xanthan gum, etc. are used alone or in combination of two or more. may be included in the composition. The abrasive is to remove the attachments on the tooth surface without damaging the tooth surface to give the original tooth gloss, calcium carbonate (CaCO 3 ), calcium phosphate dibasic (CaHPO 4 , CaHPO 4 2H 2 O), anhydrous Silicic acid (SiO 2 ·2H 2 O), aluminum hydroxide (Al(OH) 3 ), potassium pyrophosphate, magnesium carbonate, etc. may be included in the composition alone or in combination of two or more. The sweetener removes the unpleasant taste caused by the toothpaste raw material and improves the refreshing feeling, and may include saccharic acid, aspartame, xylitol, licorice acid, etc. alone or in combination of two or more kinds in the composition. The active ingredient is for preventing dental caries, periodontal disease and gingivitis, or removing bad breath, and includes fluoride, zinc chloride, chlorhexidine, aminocaproic acid, tranexamic acid, cetylpyridium chloride, pyridoxine chloride, triclosan, Tocopherol acetate, sodium monofluorophosphate, etc. may be included in the composition alone or in combination of two or more.
본 발명의 구강 조성물은 단독으로 사용하거나 또는 공지의 구강 조성물과 혼합하여 사용할 수 있다.The oral composition of the present invention may be used alone or in combination with known oral compositions.
본 발명의 다른 하나의 양태는 (a) 누에고치를 80 내지 90℃에서 6 내지 10시간 동안 열수 추출하는 단계; (b) 50 내지 55℃에서 5 내지 7시간 동안 3%(w/w) 액티나제를 상기 추출물에 처리하여 저분자 세리신을 수득하는 단계; 및 (c) 상기 저분자 세리신, 알란토인, 프로폴리스, 자일리톨, 자몽종자 추출물, 및 녹차 추출물을 혼합하는 단계;를 포함하는, 구강 조성물의 제조방법을 제공한다.Another aspect of the present invention is (a) hot water extraction of silkworm cocoons at 80 to 90 ° C. for 6 to 10 hours; (b) treating the extract with 3% (w/w) actinase at 50 to 55° C. for 5 to 7 hours to obtain low molecular weight sericin; and (c) mixing the low-molecular-weight sericin, allantoin, propolis, xylitol, grapefruit seed extract, and green tea extract.
상기 용어 "저분자 세리신", "알란토인", "프로폴리스", "자일리톨", "자몽종자 추출물", "녹차 추출물", 및 "구강 조성물"에 대한 설명은 전술한 바와 같다.The terms "low molecular weight sericin", "alantoin", "propolis", "xylitol", "grapefruit seed extract", "green tea extract", and "oral composition" are explained as described above.
본 발명의 용어 "누에고치"는 누에가 스스로 실을 토해서 몸을 감싸고 만드는 일종의 집으로서, 단백질인 약 75%의 피브로인과 약 25%의 세리신으로 구성되어 있다. 본 발명에서 상기 누에고치는 절각견, 생사, 부잠사를 모두 포함할 수 있다. 본 발명에서 상기 누에고치는 누에로부터 직접 채취하거나 시중에 판매되는 제품을 이용하는 등 그 수득 방법은 제한되지 않는다.The term "cocoon" of the present invention is a kind of house that a silkworm vomits and wraps itself around itself, and is composed of about 75% of fibroin and about 25% of sericin, which are proteins. In the present invention, the cocoon may include all of cut silk, raw silk, and floating silk. In the present invention, the method for obtaining the cocoon is not limited, such as directly collected from silkworms or using a commercially available product.
본 발명의 용어 "추출"은 용매와 추출 원료를 특정 조건 하에서 접촉시킴으로써 추출 원료에 함유된 유효성분을 분리해내는 작업을 의미한다.The term "extraction" of the present invention means an operation of separating the active ingredient contained in the extraction raw material by contacting the solvent and the extraction raw material under specific conditions.
본 발명의 용어 "액티나제(actinase)"는 식용 단백질 분해효소로서, 글루탐산 또는 아스파르트산의 카트복실 기에 있는 펩티드 결합을 주로 가수분해한다. 상기 액티나제는 화학적 또는 미생물적 방법으로 직접 수득하거나, 시중에 판매되는 제품을 구입하여 사용하는 등 그 수득 방법은 제한되지 않는다.The term "actinase" of the present invention is an edible proteolytic enzyme, which mainly hydrolyzes peptide bonds in the carboxyl group of glutamic acid or aspartic acid. The method for obtaining the actinase is not limited, such as directly obtaining it by a chemical or microbial method or purchasing and using a commercially available product.
본 발명의 또 다른 하나의 양태는 상기 구강 조성물을 포함하는 구강 청결제를 제공한다.Another aspect of the present invention provides a mouthwash containing the oral composition.
상기 용어 "구강 조성물"에 대한 설명은 전술한 바와 같다.The description of the term "oral composition" is as described above.
본 발명의 용어 "구강 청결제"는 일반적으로 구강 및 치아의 세정을 위해 사용되는 구강위생 용품으로서, 분말상, 젤상, 점액상 및 액상으로 된 제품이 주로 유통되고 있다. 구강 청결제는 구강위생 관리에 사용되는 보조 용품으로 치약, 칫솔 다음으로 사용률이 높고, 최근 다양한 종류의 구강 청결제가 출시되면서 구강 청결제의 시장 규모도 지속적으로 증가하고 있다. 그러나, 종래의 구강 청결제는 특유의 알콜 향 및 자극감을 나타내어 사용감에 대한 평가가 부정적이었으며, 장기간 사용 시 미량씩 인체 내로 섭취될 가능성이 있고, 정상 균주의 변화를 일으켜 구강 내 환경에 부정적인 영향을 미칠 가능성이 제기되고 있다. 구체적으로, 일반 가글 제품에 포함되는 알코올은 구강 내의 수분을 날아가게 하여 구강 건조증을 유발할 수 있고, 그에 따라 세균 침투가 용이하여 심혈관 질환, 치매, 폐렴 등의 원인이 될 수 있다. 또한, 살균 성분으로써 포함되는 클로르헥시딘(chlorhexidine) 성분은 산화질소(NO)를 생성하는 유익균을 파괴하여, 자주 사용하는 경우 혈압이 높아질 수 있다는 연구가 보고된 바 있으며, 프라그 제거 효과를 위한 성분인 세틸피리디늄염화물수화물(Cetylpyridinium chloride hydrate, CPC)은 치약 내 계면활성제 성분과 결합하면 치아 변색을 일으키는 것으로 보고되었다. 또한, 색소로써 포함되는 타르 성분은 그 종류나 포함되는 양에 따라 천식 또는 신경계 이상을 일으킬 수 있다는 가능성이 보고되었다. 이에, 본 발명에서는 천연 성분을 이용하여 보다 효과적이고 부작용이 적은 구강 청결제를 개발하였다.The term "mouthwash" of the present invention is an oral hygiene product generally used for cleaning the mouth and teeth, and products in the form of powder, gel, mucus and liquid are mainly distributed. Mouthwash is an auxiliary product used for oral hygiene management, and its usage rate is the second highest after toothpaste and toothbrush. However, conventional mouthwashes exhibited a unique alcohol scent and irritation, so the evaluation of the feeling of use was negative, and when used for a long time, there is a possibility of being ingested into the human body in small amounts, and it may cause changes in normal strains to negatively affect the oral environment. Possibilities are emerging. Specifically, alcohol included in general gargling products can cause dry mouth by blowing away moisture in the mouth, and thus bacteria can easily penetrate, causing cardiovascular disease, dementia, pneumonia, and the like. In addition, a study has been reported that chlorhexidine, which is included as a bactericidal component, destroys beneficial bacteria that produce nitric oxide (NO), which can increase blood pressure when used frequently. Pyridinium chloride hydrate (Cetylpyridinium chloride hydrate, CPC) has been reported to cause tooth discoloration when combined with surfactant components in toothpaste. In addition, it has been reported that the tar component included as a pigment may cause asthma or nervous system abnormalities depending on the type or amount contained. Therefore, in the present invention, a more effective mouthwash with fewer side effects was developed using natural ingredients.
본 발명의 구체적인 일 구현예에서는, 저분자 세리신, 알란토인, 프로폴리스, 자일리톨, 자몽종자 추출물, 및 녹차 추출물을 포함하는 본 발명의 조성물과 시중에 판매되는 일반 가글 제품의 관능감을 비교 평가한 결과, 일반 구강 청결제의 경우 알코올 향 때문에 향에 대한 평가가 낮았으며, 사용 시 구강 내 자극감이 심하여 부정적인 평가를 받은 것에 비하여, 본 발명의 구강 조성물은 부드러운 사용감을 나타내면서도 사용 후의 상쾌감이 유지되어 선호도가 높은 것을 확인하였다 (평가예 4).In a specific embodiment of the present invention, as a result of comparative evaluation of the sensory sensation of the composition of the present invention including low-molecular-weight sericin, allantoin, propolis, xylitol, grapefruit seed extract, and green tea extract and general gargling products sold on the market, general In the case of mouthwash, the evaluation of the fragrance was low due to the alcohol scent, and the oral composition of the present invention was highly preferred because it exhibited a soft feeling of use while maintaining a refreshing feeling after use, compared to the negative evaluation due to the severe irritation in the oral cavity when used. It was confirmed (Evaluation Example 4).
본 발명의 구강 청결제는 그 포장 형태가 제한되지 않으나, 바람직하게는 파우치 형태일 수 있으며, 더욱 구체적으로 스틱형 파우치 형태일 수 있다. 그에 따라, 상기 구강 청결제는 스틱형 파우치 형태로 제공됨으로써 간편하게 휴대할 수 있으며, 언제 어디서나 사용이 가능하다.The packaging form of the mouthwash of the present invention is not limited, but may preferably be in the form of a pouch, and more specifically, may be in the form of a stick pouch. Accordingly, since the mouthwash is provided in the form of a stick-type pouch, it can be easily carried and used anytime, anywhere.
본 발명의 구강 청결제는 알코올(alcohol), 클로르헥시딘(chlorhexidine, CHX), 염화세틸피리디늄(Cetylpyridinium chloride hydrate, CPC), 및 타르 색소(tar color)를 포함하지 않는 것을 특징으로 한다.The mouthwash of the present invention is characterized in that it does not contain alcohol, chlorhexidine (CHX), cetylpyridinium chloride hydrate (CPC), and tar color.
본 발명의 또 다른 하나의 양태는 저분자 세리신, 알란토인, 프로폴리스, 자일리톨, 자몽종자 추출물, 및 녹차 추출물을 포함하는 항균용 조성물을 제공한다.Another aspect of the present invention provides an antibacterial composition comprising low molecular weight sericin, allantoin, propolis, xylitol, grapefruit seed extract, and green tea extract.
상기 용어 "저분자 세리신", "알란토인", "프로폴리스", "자일리톨", "자몽종자 추출물", 및 "녹차 추출물"에 대한 설명은 전술한 바와 같다.The terms “low molecular weight sericin”, “alantoin”, “propolis”, “xylitol”, “grapefruit seed extract”, and “green tea extract” are explained as described above.
본 발명의 용어 "항균"은 세균 또는 진균의 생균 저해 작용을 의미하며, 구강 유해균에 대한 생장 억제 작용을 포함한다.The term "antibacterial" of the present invention means a probiotic inhibitory action of bacteria or fungi, and includes a growth inhibitory action against oral harmful bacteria.
본 발명의 항균용 조성물은 구강 내 존재하여 부정적 영향을 미치는 구강 미생물에 대해 항균 효과를 나타낼 수 있다. 본 발명에 있어서, 상기 구강 미생물로는 스트렙토코커스 뮤탄스(Streptococcus mutans), 포르피로모나스 진지발리스(Porphyromonas gingivalis), 스트렙토코커스 아레우스(Streptococcus aureus), 푸조박테리움 뉴클레아텀(Fusobacterium nucleatum), 프레보텔라 인터미디아(Prevotella intermedia), 액티노바실러스 액티노마이세텀코미탄스(Actinobacillus actinomycetemcomitans), 액티노마이세스 비스코서스(Actinomyces viscosus), 아그레가티박터 액티노마이세텀코미탄스(Aggregatibacter actinomycetemcomitans) 및 탄네렐라 포르시티아(Tannerella forsythia)로 이루어진 군에서 선택된 하나 이상의 구강 미생물일 수 있다. 구강 내 병원성 미생물은 균체 외 또는 표면으로부터 글루코실 트랜스퍼라아제(Glucosyltransferase, GTase)라는 효소를 분비함으로써 음식물 내 수크로즈(sucrose)를 기질로 하여 글루코스(glucose)와 프락토스 (fructose)를 생성하고, 동시에 글루코즈의 중합체인 불용성 글루칸(insoluble glucan)을 치면에 형성하게 된다. 형성된 글루칸에 다른 미생물들이 치면에 부착함으로써 치면 세균막, 즉, 치태(dental plaque)를 형성하게 된다. 이 치태 내에서 젖산균이 증식하여 프락토즈를 탄소원으로 젖산을 생성하고, 부착성 글루칸에 젖산이 포집 농축되고, 이렇게 농축된 고농도의 산은 치아의 구성성분인 인산칼슘 중 Ca2+를 녹아내리게하여 치아의 외막인 법랑질(enamel)을 용해시킴으로써 충치를 유발하게 된다. 또한, 구강 내 병원성 미생물은 치아 표면에 세균성 피막인 프라그를 형성하고, 프라그 내에서 증식하는 젖산균 으로부터 생성된 젖산이 고농도롤 축적됨으로써 치아의 칼슘 이온(Ca2+)이 소실된다. 이로 인해, 치아 외막 법랑질의 용해와 함께 충치가 유발되고 프라그로부터 유발된 독성 물질이 치아와 잇몸 사이의 틈새(crevice)로 스며 들어 세포내 염증 반응을 일으킴으로써 치은염, 치주염 등의 치주질환이 나타난다. 프라그에서 나오는 내독소(endotixin) 또는 지질다당체(lipopolysaccharide, LPS)로 대표되는 세균성 항원 물질은 치은 조직 내로 침입하고, 이에 의해 유도된 호중구와 대식세포는 프라그에서 나온 세균성 항원 물질을 탐식함으로써 활성화되어 교원질 가수분해효소(collagenase), 젤라틴 가수분해효소(gelatinase), 엘라스틴 가수분해효소(elastase), Cathepsin G 등의 효소를 세포 외로 방출한다. 이들 효소는 서로 협조적으로 작용해서 교원 질이나 프로테오글리칸과 같은 치은 조직의 유기 성분을 분해한다.The antibacterial composition of the present invention may exhibit an antibacterial effect on oral microorganisms that are present in the oral cavity and have a negative effect. In the present invention, the oral microorganisms include Streptococcus mutans , Porphyromonas gingivalis, Streptococcus aureus , Fusobacterium nucleatum , Prevotella intermedia ( Prevotella intermedia ), Actinobacillus actinomycetem comitans ( Actinobacillus actinomycetemcomitans ), Actinomyces viscosus ( Actinomyces viscosus ), Aggregatibacter actinomycetum comitans ( Aggregatibacter actinomycetemcomitans ) and It may be one or more oral microorganisms selected from the group consisting of Tannerella forsythia . Pathogenic microorganisms in the oral cavity secrete an enzyme called glucosyltransferase (GTase) from the surface or outside of the cell to produce glucose and fructose using sucrose in food as a substrate, At the same time, insoluble glucan, a polymer of glucose, is formed on the tooth surface. As other microorganisms attach to the tooth surface to the formed glucan, a bacterial film on the tooth surface, that is, dental plaque is formed. Within this plaque, lactic acid bacteria proliferate to produce lactic acid using fructose as a carbon source, and lactic acid is captured and concentrated in the adhesive glucan. It causes tooth decay by dissolving the outer layer of enamel. In addition, pathogenic microorganisms in the oral cavity form plaque, a bacterial film, on the surface of the teeth, and lactic acid generated from lactic acid bacteria proliferating in the plaque is accumulated in high concentrations, resulting in loss of calcium ions (Ca 2+ ) of the teeth. As a result, tooth decay is induced along with the dissolution of the outer tooth enamel, and toxic substances derived from plaque penetrate into the crevice between the tooth and the gum, causing an intracellular inflammatory reaction, resulting in periodontal diseases such as gingivitis and periodontitis. Bacterial antigenic substances, represented by endotoxin or lipopolysaccharide (LPS) from plaques, invade the gingival tissue, and neutrophils and macrophages induced by them invade the bacterial antigenic substances from plaques and are activated to form collagen. Enzymes such as collagenase, gelatinase, elastase, and Cathepsin G are released to the outside of the cell. These enzymes work cooperatively to break down organic components of gingival tissue, such as collagen and proteoglycans.
본 발명의 항균용 조성물은 스트렙토코커스 뮤탄스(Streptococcus mutans) 및 포르피로모나스 진지발리스(Porphyromonas gingivalis) 균주에 대한 항균 활성을 나타내는 것일 수 있다. 상기 스트렙토코커스 뮤탄스 및 포르피로모나스 진지발리스 균은 치아 우식증 또는 치주 질환의 원인균이 될 수 있다.The antibacterial composition of the present invention may exhibit antibacterial activity against strains of Streptococcus mutans and Porphyromonas gingivalis . The Streptococcus mutans and Porphyromonas gingivalis can be the cause of dental caries or periodontal disease.
본 발명의 용어 "스트렙토코커스 뮤탄스(Streptococcus mutans)"는 일명 충치균으로도 불리며, 치아 우식증의 주요 원인균으로도 알려져 있다. 스트렙토코커스 뮤탄스 균은 치아의 법랑질(enamel)에 서식하면서 포도당을 발효시켜 젖산(lactic acid)을 만들어 내며, 구강의 pH가 낮아지면서 구강 내 조성의 불균형을 일으킨다.The term of the present invention "Streptococcus mutans ( Streptococcus mutans )" is also known as a cavity-causing bacteria, and is also known as the main causative bacteria of dental caries. Streptococcus mutans bacteria live on tooth enamel, ferment glucose to produce lactic acid, and cause an imbalance in the composition of the oral cavity as the pH of the oral cavity decreases.
본 발명의 용어 "포르피로모나스 진지발리스(Porphyromonas gingivalis)"는 그람음성 박테리아로써, 치주염 원인균으로 알려져 있다. 포르피로모나스 진지발리스가 만들어내는 단백질 분해효소는 치주조직을 파괴하며, 그에 따라 다양한 치주질환이 발생할 수 있다.The term " Porphyromonas gingivalis " of the present invention is a gram-negative bacterium and is known as a causative agent of periodontitis. The proteolytic enzyme produced by Porphyromonas gingivalis destroys periodontal tissue, which can cause various periodontal diseases.
본 발명의 구체적인 일 구현예에서는, 저분자 세리신, 알란토인, 프로폴리스, 자일리톨, 자몽종자 추출물, 및 녹차 추출물을 상이한 중량비로 포함하는 실시예 및 비교예 조성물의 항균 활성을 비교한 결과, 저분자 세리신 10 중량부, 알란토인 40 중량부, 프로폴리스 20 중량부, 자몽종자 추출물 5 중량부, 자일리톨 10 중량부, 및 녹차 추출물 1 중량부를 포함하는 실시예 1 조성물의 구강 유해균에 대한 항균 활성이 가장 높은 것을 확인한 바 (평가예 2), 본 발명은 다양한 천연 성분들을 포함하면서 가장 우수한 항균 효과를 가지는 항균용 조성물의 혼합비를 규명한 것에 그 특징이 있다.In a specific embodiment of the present invention, as a result of comparing the antibacterial activity of the compositions of Examples and Comparative Examples containing low-molecular-weight sericin, allantoin, propolis, xylitol, grapefruit seed extract, and green tea extract in different weight ratios, 10% by weight of low-molecular-weight sericin It was confirmed that the composition of Example 1 containing 40 parts by weight of allantoin, 20 parts by weight of propolis, 5 parts by weight of grapefruit seed extract, 10 parts by weight of xylitol, and 1 part by weight of green tea extract had the highest antibacterial activity against harmful oral bacteria. (Evaluation Example 2), the present invention is characterized by identifying the mixing ratio of the antibacterial composition having the best antibacterial effect while including various natural ingredients.
본 발명의 구강용 조성물은 우수한 구취 제거 활성을 가지며, 기존의 구강 청결제에 비하여 저자극이고, 파우치 형태로서 그 사용이 간편한 것에 특징이 있다.The composition for oral cavity of the present invention has an excellent activity for removing bad breath, is less irritating than conventional mouthwashes, and is easy to use in the form of a pouch.
이하 본 발명을 실시예를 통하여 보다 상세하게 설명한다. 그러나 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 국한되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. However, these examples are intended to illustrate the present invention by way of example, and the scope of the present invention is not limited to these examples.
제조예 1. 세리신의 제조Preparation Example 1. Preparation of Sericin
누에고치로부터 불순물을 제거한 후 시료 중량의 10배량의 정제수를 가하여 80~90℃의 열수로 교반기를 이용해 8시간 동안 추출하여 추출물을 제조하였다. 제조된 추출물에 액티나제(actinase) 또는 플라보르자임(flavourzyme) 효소를 3%(w/w) 농도로 55℃에서 6시간 동안 처리한 후 여과하여 세리신 용액을 얻었다. 이때, 세리신 단백질의 산화를 방지하기 위하여 10~20분간 질소 가스를 충진시키고, 효소의 활성을 제거하기 위하여 110℃에서 20분간 처리한 후, 농축 및 동결건조하여 세리신 분말을 회수하였다.After removing impurities from the silkworm cocoon, 10 times the weight of the sample was added with purified water, and extracted with hot water at 80 to 90 ° C for 8 hours using a stirrer to prepare an extract. The prepared extract was treated with actinase or flavourzyme enzyme at a concentration of 3% (w/w) at 55° C. for 6 hours and then filtered to obtain a sericin solution. At this time, nitrogen gas was filled for 10 to 20 minutes to prevent oxidation of sericin protein, treated at 110 ° C. for 20 minutes to remove enzyme activity, and then concentrated and freeze-dried to recover sericin powder.
평가예 1. 분자량에 따른 세리신의 항염 활성 평가Evaluation Example 1. Evaluation of anti-inflammatory activity of sericin according to molecular weight
제조예 1에서 액티나제 또는 플라보르자임 효소를 처리하여 수득한 세리신의 분자량을 측정하였다. 그 결과는 다음 표 1에 나타내었다.The molecular weight of sericin obtained by treatment with actinase or flavorzyme enzyme in Preparation Example 1 was measured. The results are shown in Table 1 below.
상기 표 1의 결과에 따라, 저분자량을 나타내는 액티나제 처리 세리신 및 상대적으로 고분자량을 나타내는 플라보르자임 처리 세리신의 in vitro 항염 활성을 비교하였다. 구체적으로, HGF-1 (human gingival fibroblast) 치은세포를 1×106 cells/well 농도로 24-well plate에 접종하고, 5% CO2 인큐베이터에서 배양하였다. 이후, 1μg/ml의 Pg-LPS를 처리하여 염증을 유도하고, 저분자 및 고분자 세리신을 150μg/ml의 농도로 처리하였다. 24시간 배양 후, 배양 배지를 원심분리하여 얻어진 상층액의 염증성 사이토카인인 IL-6 및 IL-8의 발현량을 ELISA kit를 이용하여 정량하였다.According to the results of Table 1, the in vitro anti-inflammatory activity of actinase-treated sericin having a low molecular weight and flavorzyme-treated sericin having a relatively high molecular weight was compared. Specifically, HGF-1 (human gingival fibroblast) gingival cells were inoculated into a 24-well plate at a concentration of 1×10 6 cells/well, and cultured in a 5% CO 2 incubator. Thereafter, inflammation was induced by treatment with 1 μg/ml of Pg-LPS, and low-molecular and high-molecular sericins were treated at a concentration of 150 μg/ml. After culturing for 24 hours, the expression levels of IL-6 and IL-8, which are inflammatory cytokines, in the supernatant obtained by centrifuging the culture medium were quantified using an ELISA kit.
(pg/ml)IL-6 expression level
(pg/ml)
(pg/ml)IL-8 expression level
(pg/ml)
그 결과 상기 표 2에 나타난 바와 같이, Pg-LPS를 처리한 경우 염증성 사이토카인인 인터루킨-6 및 인터루킨-8의 발현량이 크게 증가하였으나, 세리신을 처리한 결과 그 발현량이 억제되는 것을 확인하였다. 특히, 고분자 세리신을 처리한 경우에 비하여, 액티나제 처리를 통해 수득한 저분자 세리신을 처리한 경우 LPS 유도에 의한 IL-6 및 IL-8의 발현량이 더욱 크게 감소한 바, 이를 통해 세리신의 분자량에 따라 항염 활성에 차이가 있으며, 저분자 세리신이 치은세포의 염증 억제에 있어서 더욱 우수한 염증 억제 효과를 가지는 것을 알 수 있었다.As a result, as shown in Table 2 above, when treated with Pg-LPS, the expression levels of interleukin-6 and interleukin-8, which are inflammatory cytokines, increased significantly, but as a result of treatment with sericin, it was confirmed that their expression levels were suppressed. In particular, compared to the case of treatment with high-molecular sericin, when the low-molecular sericin obtained through actinase treatment was treated, the expression levels of IL-6 and IL-8 by LPS induction were more significantly reduced, thereby affecting the molecular weight of sericin. It was found that there is a difference in anti-inflammatory activity according to the anti-inflammatory activity, and that low-molecular sericin has a more excellent anti-inflammatory effect in suppressing inflammation of gingival cells.
제조예 2. 구강 조성물의 제조Preparation Example 2. Preparation of oral composition
저분자 세리신 (액티나제 처리), 알란토인, 프로폴리스, 자일리톨, 자몽종자 추출물, 및 녹차 추출물을 다음 표 3의 중량비에 따라 포함하는 실시예 및 비교예의 구강 조성물을 제조하였다. Oral compositions of Examples and Comparative Examples containing low molecular weight sericin (actinase treatment), allantoin, propolis, xylitol, grapefruit seed extract, and green tea extract according to the weight ratios shown in Table 3 below were prepared.
상기 조성에 따라 혼합한 후, 각 조성물 50mg을 증류수 20ml에 희석하여 시료로 사용하였다.After mixing according to the above composition, 50 mg of each composition was diluted in 20 ml of distilled water and used as a sample.
평가예 2. 항균 활성 평가Evaluation Example 2. Evaluation of antibacterial activity
구강 내에 존재하는 유해균인 스트렙토코커스 뮤탄스(Streptococcus mutans) 및 포르피로모나스 진지발리스(Porphyromonas gingivalis) 균주에 대한 항균 활성을 평가하였다. 구체적으로, ATCC Medium 260 배지에 상기 구강 미생물을 0.1ml 도말하고, 실시예 및 비교예 구강 조성물 10μl를 점적한 후 건조시켰다. 이후, 혐기성 챔버에서 37℃, 2일간 배양한 후, 저해환(inhibitory zone)의 크기를 측정하였다. Streptococcus mutans , which is a harmful bacterium present in the oral cavity, and Porphyromonas gingivalis ( Porphyromonas gingivalis ) were evaluated for antibacterial activity against strains. Specifically, 0.1 ml of the oral microorganism was smeared on ATCC Medium 260 medium, and 10 μl of the oral composition of Examples and Comparative Examples was dripped and then dried. Then, after culturing for 2 days at 37° C. in an anaerobic chamber, the size of the inhibition zone was measured.
그 결과 상기 표 4에 나타난 바와 같이, 실시예 1 조성물이 스트렙도코커스 뮤탄스 및 포르피로모나스 진지발리스 균주 모두에 대한 항균 활성이 가장 우수한 바, 프로폴리스 함량이 높은 비교예 1 보다도 높은 항균 활성을 나타내었다. 반면에, 비교예 2 및 3 조성물의 항균 활성이 비교적 낮은 것을 확인하였다.즉, 본 발명의 구강 조성물은 세리신, 알란토인, 프로폴리스, 자일리톨, 자몽종자 추출물, 및 녹차 추출물을 일정 중량비로 혼합함으로써 구강 미생물의 생장을 억제하는 효과를 가지며, 그에 따라 구강 유해균으로 인한 구강 질환의 개선에 도움을 줄 수 있음을 알 수 있다.As a result, as shown in Table 4, the composition of Example 1 has the best antibacterial activity against both strains of Streptococcus mutans and Porphyromonas gingivalis. showed On the other hand, it was confirmed that the antibacterial activity of the compositions of Comparative Examples 2 and 3 was relatively low. That is, the oral composition of the present invention is obtained by mixing sericin, allantoin, propolis, xylitol, grapefruit seed extract, and green tea extract in a constant weight ratio. It can be seen that it has an effect of inhibiting the growth of microorganisms, and thus can help improve oral diseases caused by oral harmful bacteria.
평가예 3. 구취 제거 활성 평가Evaluation Example 3. Evaluation of bad breath removal activity
구취를 유발하는 물질인 주요 황 화합물 중 하나인 methyl mercaptan의 표준액 2ml를 에탄올 198ml 용액에 용해하여 준비하였다. 시료를 첨가하지 않은 증류수를 대조군으로 선정하고, 실시예 및 비교예 시료 4ml에 0.2M potassium phosphate buffer 1ml를 넣어 pH 7.5로 조절하였다. 여기에, methyl mercaptan 표준액 1ml를 가한 즉시 실리콘 캡으로 밀봉하여 5초간 교반하고, 37℃에서 6분간 반응시킨 후 100μl를 취하여 FPD(flame photometric detector)가 장착된 gas chromatography에 주입하여 methyl mercaptan 함량을 측정하였다. 구취 억제 활성(%)은 (대조군 methyl mercaptan 피크면적 - 시료 첨가 시 methyl mercaptan 피크면적) / 대조군 methyl mercaptan 피크면적 x 100으로 계산하였다.It was prepared by dissolving 2 ml of a standard solution of methyl mercaptan, one of the main sulfur compounds that causes halitosis, in 198 ml of ethanol. Distilled water to which no sample was added was selected as a control, and pH was adjusted to 7.5 by adding 1ml of 0.2M potassium phosphate buffer to 4ml of samples of Examples and Comparative Examples. Here, 1ml of methyl mercaptan standard solution was added, immediately sealed with a silicone cap, stirred for 5 seconds, reacted at 37 ° C for 6 minutes, and then 100 μl was taken and injected into gas chromatography equipped with a flame photometric detector (FPD) to measure the methyl mercaptan content did Halitosis inhibitory activity (%) was calculated as (control methyl mercaptan peak area - methyl mercaptan peak area when sample was added) / control methyl mercaptan peak area x 100.
그 결과 상기 표 5에 나타난 바와 같이, 실시예 1 조성물이 약 80%로 우수한 구취 억제 활성을 나타내었으며, 다음으로 비교예 2, 비교예 3, 비교예 4, 비교예 1 조성물의 순으로 나타났다. 즉, 본 발명의 구강 조성물은 세리신, 알란토인, 프로폴리스, 자일리톨, 자몽종자 추출물, 및 녹차 추출물을 일정 중량비로 혼합함으로써 구취 억제 활성을 가짐을 확인하였다.As a result, as shown in Table 5, the composition of Example 1 exhibited an excellent halitosis inhibitory activity at about 80%, followed by the compositions of Comparative Example 2, Comparative Example 3, Comparative Example 4, and Comparative Example 1 in that order. That is, it was confirmed that the oral composition of the present invention has a bad breath inhibitory activity by mixing sericin, allantoin, propolis, xylitol, grapefruit seed extract, and green tea extract in a constant weight ratio.
평가예 4. 관능 평가Evaluation Example 4. Sensory evaluation
본 발명 구강 조성물의 선호도를 평가하기 위하여 실시예 1 조성물 및 시판되는 구강 청결제(비교예 5)를 대상으로 비교 관능평가를 실시하였다. 구체적으로, 20 ~ 40 대의 성인남녀 20명을 선정하고, 흰 종이컵에 10ml의 시료를 담아 제시하였다. 각 시료를 입안에 머금은 시간은 총 30초이며, 이 시간 내에 3회 가글하도록 하였다. 관능평가 항목은 향, 자극감, 사용 후 상쾌감, 및 전제적인 선호도에 대해 10점 척도로 평가하였고, 선호도가 높을수록 높은 점수를 주도록 하였다. In order to evaluate the preference of the oral composition of the present invention, a comparative sensory evaluation was conducted on the composition of Example 1 and a commercially available mouthwash (Comparative Example 5). Specifically, 20 adult men and women in their 20s and 40s were selected and presented with 10ml samples in white paper cups. The time each sample was held in the mouth was 30 seconds in total, and it was gargled 3 times within this time. Sensory evaluation items were evaluated on a 10-point scale for fragrance, stimulation, feeling of refreshment after use, and overall preference, and the higher the preference, the higher the score.
상기 표 6에 나타난 바와 같이, 본 발명의 실시예 1 조성물이 시판 구강 청결제에 비하여 모든 평가 및 전반적인 선호도가 높은 것을 확인하였다. 특히, 일반 구강 청결제의 경우 알코올 향 때문에 향에 대한 평가가 낮았으며, 사용 시 구강 내 자극감이 심하여 부정적인 평가를 받았다. 그에 반해, 본 발명의 구강 조성물은 부드러운 사용감을 나타내면서도 사용 후의 상쾌감이 유지되는 것을 확인하였다.As shown in Table 6, it was confirmed that the composition of Example 1 of the present invention was higher in all evaluations and overall preference than commercially available mouthwashes. In particular, in the case of general mouthwash, the evaluation of the fragrance was low because of the alcohol scent, and it received a negative evaluation due to severe irritation in the mouth when used. In contrast, it was confirmed that the oral composition of the present invention maintains a refreshing feeling after use while exhibiting a soft feeling of use.
이상의 설명으로부터, 본 발명이 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, those skilled in the art to which the present invention pertains will be able to understand that the present invention may be embodied in other specific forms without changing its technical spirit or essential features. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not limiting. The scope of the present invention should be construed as including all changes or modifications derived from the meaning and scope of the claims to be described later and equivalent concepts rather than the detailed description above are included in the scope of the present invention.
Claims (1)
상기 저분자 세리신은 누에고치를 열수 추출 후, 액티나제(actinase)를 처리하여 제조되는 것인, 구취 억제용 구강 조성물.5 to 15 parts by weight of low molecular weight sericin with a molecular weight of 2,000 to 3,000 Da, 35 to 45 parts by weight of allantoin, 15 to 25 parts by weight of propolis, 5 to 15 parts by weight of xylitol, 0.1 to 10 parts by weight of grapefruit seed extract, and 0.1 to 10 parts by weight of green tea extract 3 parts by weight,
The low-molecular-weight sericin is prepared by extracting silkworm cocoons with hot water and then treating actinase (actinase), oral composition for suppressing bad breath.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210185136A KR20230046177A (en) | 2021-09-24 | 2021-12-22 | Oral composition comprising sericin for inhibiting the halitosis |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210126421 | 2021-09-24 | ||
| KR20210126975 | 2021-09-27 | ||
| KR1020210127759A KR102343906B1 (en) | 2021-09-24 | 2021-09-28 | Oral composition comprising sericin |
| KR1020210185136A KR20230046177A (en) | 2021-09-24 | 2021-12-22 | Oral composition comprising sericin for inhibiting the halitosis |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210127759A Division KR102343906B1 (en) | 2021-09-24 | 2021-09-28 | Oral composition comprising sericin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230046177A true KR20230046177A (en) | 2023-04-05 |
Family
ID=79178081
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210127759A KR102343906B1 (en) | 2021-09-24 | 2021-09-28 | Oral composition comprising sericin |
| KR1020210185143A KR20230046178A (en) | 2021-09-24 | 2021-12-22 | Manufacturing method of oral cleaner composition |
| KR1020210185136A KR20230046177A (en) | 2021-09-24 | 2021-12-22 | Oral composition comprising sericin for inhibiting the halitosis |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210127759A KR102343906B1 (en) | 2021-09-24 | 2021-09-28 | Oral composition comprising sericin |
| KR1020210185143A KR20230046178A (en) | 2021-09-24 | 2021-12-22 | Manufacturing method of oral cleaner composition |
Country Status (1)
| Country | Link |
|---|---|
| KR (3) | KR102343906B1 (en) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100447428B1 (en) * | 1996-08-05 | 2005-06-23 | 주식회사 엘지생활건강 | Oral solution composition |
| KR100286388B1 (en) * | 1998-03-14 | 2001-05-02 | 대한민국 | Method for preparing silk power peptide by enzymatic degradation |
| KR100613989B1 (en) * | 2005-01-27 | 2006-11-23 | 대한민국(관리부서:농촌진흥청) | Composition for oral care product including nano silk carrier |
| JP2009203167A (en) * | 2008-02-26 | 2009-09-10 | Kracie Home Products Ltd | Cytokine production inhibitor and cosmetic composition comprising the same |
| KR101893598B1 (en) * | 2016-06-10 | 2018-10-04 | (주)라파프로폴리스 | A toothpaste composition without bubbles, and the toothpaste manufactured with the composition |
| KR102112827B1 (en) * | 2018-10-12 | 2020-05-25 | 주식회사 세리코 | A composition for improving a skin and a method of preparing the composition |
| KR102133753B1 (en) * | 2018-11-09 | 2020-07-16 | 대한민국(농촌진흥청장) | Oral composition containing silk protein, 4-hexylresorcinol and natural oil |
-
2021
- 2021-09-28 KR KR1020210127759A patent/KR102343906B1/en active IP Right Grant
- 2021-12-22 KR KR1020210185143A patent/KR20230046178A/en unknown
- 2021-12-22 KR KR1020210185136A patent/KR20230046177A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102343906B1 (en) | 2021-12-28 |
| KR20230046178A (en) | 2023-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101723588B1 (en) | Composition for mouth comprising camellia japonica l leaf extract and manufacturing method thereof | |
| US20090269288A1 (en) | Black pearl toothpaste | |
| KR101354923B1 (en) | Oral hygiene composition using an extract of curcuma longa and an extract eriobotrya japonica | |
| JP7463429B2 (en) | Oral Composition | |
| KR101635861B1 (en) | Oral composition containing fermentative extract of galla rhoids as active ingredient | |
| KR19980013946A (en) | Oral composition of liquid type | |
| JP2016504279A (en) | Oral care composition containing theaflavin extract | |
| KR101660467B1 (en) | Oral composition containing fermentative extract of lycii fructus as active ingredient | |
| KR102343906B1 (en) | Oral composition comprising sericin | |
| KR20170103476A (en) | Composition for prevention or treatment of oral disease comprising ROSAE LAEVIGATAE Extract | |
| US20060147391A1 (en) | Composition for enhancing oral health | |
| WO2022092522A1 (en) | Oral composition for ameliorating bad breath | |
| KR102328978B1 (en) | An oral composition for improvement of periodontal disease comprising natural complex extracts | |
| KR101875191B1 (en) | Composition for mouth comprising tengcha | |
| KR102665309B1 (en) | Composition for prevention or treatment of oral disease comprising Cordycepin | |
| KR102665310B1 (en) | Composition for prevention or treatment of oral disease comprising Verbascoside | |
| KR102597684B1 (en) | Oral composition comprising amaranth extract | |
| KR20020082308A (en) | Composition for the mouth containing extraction of Euonymus alatus Sieb | |
| KR101344803B1 (en) | Oral care composition comprising extract of machilus thunbergii and sequestering agent | |
| KR101570789B1 (en) | Dental hygienic composition including hemoloymph from silkworm larvae | |
| KR102670487B1 (en) | Composition for prevention or treatment of oral disease comprising cynarin | |
| KR102657494B1 (en) | Composition for prevention or treatment of oral disease comprising lithospermic acid | |
| KR20170103482A (en) | Composition for prevention or treatment of oral disease comprising Glechoma hederacea extract | |
| KR20170103494A (en) | Composition for prevention or treatment of oral disease comprising Melonis Pedicellus Extract | |
| KR102597685B1 (en) | Oral composition comprising parsley extract |